University of California Minority Patient-Derived Xenograft (PDX) Development and Trial Center (UCaMP) to Reduce Cancer Health Disparities

Overview

About this study

The purpose of this study is to establish at least 200 patient-derived cancer xenografts (PDXs), and to utilize these PDXs in preclinical testing of single agents and drug combinations to guide precision cancer medicine decision-making with a focus upon the predominant racial/ethnic minority populations residing in California.

 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients, 21-100 years old, inclusive.
  • Diagnosed with one of the four types of cancers:
    • bladder cancer;
    • lung cancer;
    • gastric/stomach cancer;
    • liver cancer,
  • Seen in routine clinic appointments within the UC Davis Health System and contributing UCaMP institutions. 
  • Willing and able to provide signed Informed Consent.

Exclusion Criteria:

  • Specimen unacceptable/degraded/etc.
  • Individuals who are not yet adults (infants, children, teenagers).
  • Pregnant women.
  • Prisoners.
  • Adults unable to consent.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Gerardo Colon-Otero, M.D.

Open for enrollment

Contact information:

Muriel Rabalais

(904) 953-3570

Rabalais.Muriel@mayo.edu

More information

Publications

Publications are currently not available
.

Mayo Clinic Footer